Researchers conducted a systematic review of randomized controlled trials comparing intravenous opioids to low-dose ketamine for pain relief in the ED. They identified three studies for inclusion in a meta‐analysis.
The study shows ketamine was not inferior to morphine with regard to pain scale reduction. However, while no severe adverse events were reported in any study, higher rates of non-severe adverse events were observed with ketamine.
“Ketamine is noninferior to morphine for the control of acute pain,” study authors concluded.
More artilces on opioids:
This state leads the US in driving down opioid prescriptions, says BCBS report
Construction workers hit hard by opioid epidemic — Here’s what 1 trade group is doing about it
3 ways art therapy helps pain management
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
